Jason Mast

diseases, if it's going to be so resource intensive for one patient, there's going to have to be considerations about, you know, you can, the less testing you require, the more patients you can treat. So there's going to have to be discussions around how much testing you do and what is safe and what is a good bar for efficacy and who pays for this, which diseases are

require this versus that you're going to have to demand a lot more testing, as I was saying. And those will be a bunch of ethical questions that the field will have to figure out and will not be easy. A few people are in favor of this overall, but the question is when and for who and who pays and a lot of naughty issues on the horizon.

require this versus that you're going to have to demand a lot more testing, as I was saying. And those will be a bunch of ethical questions that the field will have to figure out and will not be easy. A few people are in favor of this overall, but the question is when and for who and who pays and a lot of naughty issues on the horizon.

require this versus that you're going to have to demand a lot more testing, as I was saying. And those will be a bunch of ethical questions that the field will have to figure out and will not be easy. A few people are in favor of this overall, but the question is when and for who and who pays and a lot of naughty issues on the horizon.